Mineralocorticoid receptor antagonists for heart failure

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 18, 2011, Pages 2767-2769

  Funder, John ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MINERALOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR ANTAGONIST; RECEPTOR BLOCKING AGENT; SPIRONOLACTONE; UNCLASSIFIED DRUG;

DRUG INDICATION; DRUG MECHANISM; ESSENTIAL HYPERTENSION; HEART FAILURE; HUMAN; PRESCRIPTION; RECEPTOR BLOCKING; REVIEW;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; HEART FAILURE; HUMANS; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE;

EID: 81855205305     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.635515     Document Type: Review

References (11)

1. Mineralocortoid receptor antagonists for heart failure. Expert Opin Pharmacother 2011
2. Gros R, Ding Q, Sklar L, et al. GPR 30 expression is required for the mineralocortoid receptor-independent rapid vascular effects of aldosterone. Hypertension 2011;57:442-51
3. Rickard AJ, Morgan J, Tesch G, et al. Deletion of mineralocortoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 2009;54:537-43
4. Mihailidou AS, Loan Le TY, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009;54:1306-12
5. Funder JW. Cardiac synthesis of aldosterone: going, going, gone? Endocrinology 2004;145:4793-5
6. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-8
7. Levy D, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of aldosterone. J Clin Endocr Metab 2004;89:2736-40
8. Epstein M, Buckalew V, Martinez FJ, et al. Antiproteinuric effects of eplerenone, enalapril, and eplerenone/ enalapril combination in diabetic hypertensives with microalbuminuria. Am J Hypertens 2002;15:24A Abstract
9. Nishizuka M, Zaman M, Calhoun A. Efficiency of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-30
10. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. Endocrinology 2008;93:3266-81
11. Sechi L, Colussi G, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens 2010;23:1253-60